Looks like MSB are not involving a partner.
No matter what is promoted on here, even if Mesoblast received a quick sr-GVHD approval in 2024 we don't have the funds to complete this CLBP trial on our own without $ from somewhere like a partnership deal ? It doesn't necessarily have to be a CLBP partnership deal; funds would also be incoming through a CHF partnership deal but again on our own reliant totally on Remestemcel-L revenues from a quick FDA approval - not going to happen IMO
..... oh and of course don't even get me started on if we receive another CRL
GLTAH
Ann: Confirmatory Phase 3 Back Pain Trial Actively Enrols, page-16
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
-0.048(3.15%) |
Mkt cap ! $1.681B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $5.871M | 4.004M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 17231 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 27594 | 9 |
View Market Depth
| Last trade - 13.57pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |